ChREBP was downregulated in patients with NAFLD compared to healthy controls, and instead, SREBP1c was shown to be one of the predominant regulators of DNL in NAFLD [97]. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.